DOCSLIB.ORG

Hydrocortisone Butyrate 0.1% Cream in the Treatment of Chronic Dermatitis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hydrocortisone Butyrate 0.1% Cream in the Treatment of Chronic Dermatitis THERAPEUTICS FOR THE CLINICIAN Hydrocortisone Butyrate 0.1% Cream in the Treatment of Chronic Dermatitis Joseph F. Fowler, Jr, MD; Anthony F. Fransway, MD; J. Mark Jackson, MD; Nestor Rohowsky, MA This multicenter, randomized, double-blind clini- opical corticosteroids remain the mainstay cal trial involving 89 subjects (86 with chronic of therapy for inflammatory skin conditions hand dermatitis and 3 with atopic dermatitis) T such as hand dermatitis and atopic dermati- compared the safety, efficacy, and cosmetic tis.1,2 The appearance of treatment alternatives acceptability of 4 medium-potency topical corti- involving combinations of corticosteroids with costeroid products: hydrocortisone butyrate newer immunomodulating agents3,4 has led to an (HB) 0.1% cream (Locoid Lipocream®), flutica- increase in the demand for a variety of treatment sone propionate (FP) 0.05% cream (Cutivate®), options, including corticosteroids of different prednicarbate (PC) 0.1% cream (Dermatop®), and potencies and in different vehicles. Use of the mometasone furoate (MF) 0.1% cream (Elocon®). various treatment options is highly individualized, Subjects were randomly assigned to 1 of 3 treat- based on factors such as extent and severity of the ment groups (HB vs FP, HB vs PC, or HB vs MF) condition, treatment history, patient age, allergic and further randomized to HB on the right or the and irritant sensitivity, and cosmetic acceptabil- left side, and FP, PC, or MF on the contralateral ity. This clinical trial was undertaken to evaluate side. Treatments were self-administered twice daily the safety, efficacy, and cosmetic acceptability of a for 2 weeks. Assessments of efficacy were based high-lipid emollient cream formulation of hydro- on the investigator ratings of signs and the sub- cortisone butyrate (HB) 0.1% (Locoid Lipocream®) ject ratings of signs and symptoms. Cosmetic as compared with 3 other medium-potency acceptability was assessed by direct compar- corticosteroid cream products—fluticasone propi- isons between products using a subject ques- onate (FP) 0.05% cream (Cutivate®), prednicar- tionnaire. The results indicated comparable bate (PC) emollient 0.1% cream (Dermatop®), efficacy of all 4 medium-potency corticosteroid and mometasone furoate (MF) 0.1% cream products and suggested that, compared to other (Elocon®)—in the treatment of chronic atopic corticosteroid creams, the HB vehicle yielded and hand dermatitis. somewhat greater subject preference with respect to cosmetic appeal. Methods Cutis. 2005;75:125-131. Subjects—Subjects were included in the study pop- ulation if they were between 18 and 65 years of age with moderate hand dermatitis or atopic dermatitis that had persisted for at least 2 weeks prior to their Accepted for publication August 6, 2004. entering the study. The study was designed to make Drs. Fowler and Jackson are from the University of Louisville School of Medicine, Kentucky. Dr. Fransway is from Fort Meyers, unbiased within-subject comparisons of treatment Florida. Mr. Rohowsky is from Integrated Data Consultation effectiveness; therefore, subjects had to have Services, Inc, La Grange Park, Illinois. approximately symmetrical bilateral involvement at This study was supported by a grant from Ferndale Laboratories, the baseline visit. A total of 89 subjects (86 with Inc. Dr. Fowler is a consultant and investigator and Mr. Rohowsky hand dermatitis and 3 with atopic dermatitis) were is a consultant for Ferndale Laboratories, Inc. Drs. Fransway and Jackson report no conflict of interest. randomized to the study. Subjects could not use Reprints: Joseph F. Fowler, Jr, MD, 444 S First St, Louisville, other medications known to affect dermatitis, KY 40202 (e-mail: [email protected]). including systemic treatments, for one month prior VOLUME 75, FEBRUARY 2005 125 Hydrocortisone Butyrate for Chronic Dermatitis to the baseline visit or topical corticosteroids for HB on the right or the left side, and FP, PC, or MF one week prior to the baseline visit. on the contralateral side. At the baseline study Study Design—This was a multicenter, random- visit, subjects were instructed in the use of the ized, double-blind, controlled clinical trial of 2 weeks’ study products. Subjects also made their first appli- duration. Subjects were randomized in balanced cation of the products under supervision of the cohorts to 3 parallel-treatment groups, each group clinical staff. For the next 2 weeks, the subjects receiving a pair of treatments, HB vs FP, HB vs self-administered the treatments twice daily fol- PC, or HB vs MF. All subjects were treated with lowing written instructions. The instructions Table 1. Clinical Assessments of Dermatitis Severity Score Sign/Symptom 0ϭNone 1ϭMild 2ϭModerate 3ϭSevere Erythema None Mild pinkness Moderate pink to red Intense redness Cracking/fissuring None A few shallow Moderate, early fissures Deep fissures (1 mm) cracks Scaling None Diffuse mild Moderate, with or Thick scaling plaques flaking without plaques Papules/vesicles None A few Multiple Large bullae papules/vesicles papules/vesicles, or widespread contained papules/vesicles Table 2. Percentage of Subjects Showing Improvement in Signs of Dermatitis*† Treatment HB vs FP (nϭ26) HB vs PC (nϭ28) HB vs MF (nϭ31) Sign Rated by HB FP HB PC HB MF Erythema Investigator 31 23 46 46 42 39 Subject 50 35 46 39 61 52 Cracking/fissuring Investigator 62 54 43 21 48 42 Subject 46 50 43 43 48 52 Scaling Investigator 65 54 43 54 48 48 Subject 54 54 43 61 48 42 Papules/vesicles Investigator 27 23 36 36 26 19 Subject 27 15 21 29 19 10 *HB indicates hydrocortisone butyrate 0.1% cream; FP, fluticasone propionate 0.05% cream; PC, prednicarbate emollient 0.1% cream; MF, mometasone furoate 0.1% cream. †Individual pairwise comparisons were statistically significant (PϽ.05) only for subject rating of erythema in the HB vs FP group and investigator rating of cracking/fissuring in the HB vs PC group. 126 CUTIS® Hydrocortisone Butyrate for Chronic Dermatitis Table 3. Mean Investigator Total Signs Score Ϯ SD* Treatment HB vs FP (nϭ26) HB vs PC (nϭ28) HB vs MF (nϭ31) HB FP HB PC HB MF Baseline 4.9Ϯ1.1 4.8Ϯ1.2 5.0Ϯ1.3 5.1Ϯ1.3 5.1Ϯ1.5 5.1Ϯ1.7 Final 3.3Ϯ2.4 3.7Ϯ2.4 3.4Ϯ1.3 3.8Ϯ1.7 3.6Ϯ2.2 3.4Ϯ2.3 Change from baseline Ϫ1.6Ϯ2.0 Ϫ1.2Ϯ2.2 Ϫ1.6Ϯ1.7 Ϫ1.3Ϯ1.3 Ϫ1.5Ϯ1.7 Ϫ1.7Ϯ1.6 Within-treatment P value .0004 .0112 Ͻ.0001 Ͻ.0001 Ͻ.0001 Ͻ.0001 Between-treatment .0626 .3493 .5195 P value (within group) *HB indicates hydrocortisone butyrate 0.1% cream; FP, fluticasone propionate 0.05% cream; PC, prednicarbate emollient 0.1% cream; MF, mometasone furoate 0.1% cream. included details regarding the application of Safety Assessments—Product safety was assessed specifically labeled products (labeled “left” or through the collection and evaluation of adverse “right”) to the appropriate side of the body using events, either observed by the investigator or volun- new vinyl gloves at each application to prevent the teered by the subjects. intermixing of the materials from one side to the Statistical Analysis—Changes from baseline to other. The medications were dispensed to the sub- final visit for each investigator’s signs score and jects in blind-labeled tubes that were clearly each subject’s signs and symptoms score were cate- marked with the subject’s identification number gorized as “improved,” “worsened,” or “no change.” and the word “left” or “right.” At the end of the The distribution of subjects across these 3 cate- 2-week treatment period, the subjects returned to gories was then compared between treatments using the study site for a final examination. the McNemar test. The investigator total scores, Clinical Assessments—As shown in Table 1, at the subject total scores, and in patients with hand the baseline and final visits, the investigators and dermatitis, the percentage of hand involvement the subjects independently rated the severity of (palm, dorsum, and combined) were analyzed typical signs of dermatitis using a 4-point ordinal within treatment group using the t test for paired scale (0ϭnone, 1ϭmild, 2ϭmoderate, and data. The scores and percentages were analyzed 3ϭsevere). In addition, the subject rated 2 addi- between treatment groups using comparisons of tional symptoms, pruritus and pain/burning. The changes from baseline derived from the results of total signs score for investigators was calculated the t test for paired data. Demographic and back- by summing the separate signs scores. The total ground parameters were compared between treat- signs and symptoms score for subjects was calcu- ment groups using analysis of variance and ␹2 tests, lated by summing each patient’s signs and symp- as appropriate. No statistical tests were performed toms scores. The percentage of hand involvement for the questionnaire responses or the incidence of for hand dermatitis or the size of the target area for adverse events. atopic dermatitis also was recorded. Subject Questionnaires—At the final visit, sub- Results jects completed a questionnaire in which they com- Subjects—A total of 89 subjects were enrolled in pared both study products with respect to which the study; 27 were randomized to the HB versus FP cream felt more soothing upon application, which group, 28 to the HB versus PC group, and 34 to the cream moisturized the skin better, and which cream HB versus MF group. The mean overall age of sub- was preferred overall. jects was 46 years old; 52 of the subjects (58%) VOLUME 75, FEBRUARY 2005 127 Hydrocortisone Butyrate for Chronic Dermatitis 6 5 5.1 5.1 5 4.8 4 3.7 3.8 3.4 3.4 3 Total Score 2 1 0 HB* FP PC MF Product A 9 8 7.4 7.1 7.2 Figure 1. Mean investigator 7 7 total signs score (A) and mean subject total signs 6 and symptoms score (B).
Load more

Recommended publications
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Clinical Policy: Topical Agents: Corticosteroids
    Clinical Policy: Topical Agents: Corticosteroids Reference Number: OH.PHAR.PPA.92 Effective Date: 01/01/2020 Revision Log Last Review Date: Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description TOPICAL AGENTS: CORTICOSTEROIDS – LOW POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON- PREFERRED” DESONIDE cream, ointment (generic of Desowen®) ALCLOMETASONE cream, ointment (generic of FLUOCINOLONE ACETONIDE 0.01% cream, solution Aclovate®) (generic of Synalar®) CAPEX® shampoo (fluocinolone acetonide) FLUOCINOLONE body oil, scalp oil (generic of Derma- DESONATE®gel (desonide) Smoothe/ FS®) DESONIDE lotion (generic of Desowen®) HYDROCORTISONE cream, lotion, ointment HYDROCORTISONE ACETATE WITH ALOE gel HYDROCORTISONE WITH UREA cream (generic of Carmol HC®) PANDEL® cream (hydrocortisone probutate) PEDIADERM HC® kit TOPICAL AGENTS: CORTICOSTEROIDS – MEDIUM POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON--PREFERRED” BETAMETHASONE DIPROPIONATE-CALCIPOTRIENE BETAMETHASONE DIPROPIONATE lotion (generic of Ointment Diprolene®) BETAMETHASONE VALERATE cream, lotion (generic of CLOCORTOLONE PIVALATE (generic of Cloderm®) Valisone®) CORDRAN® tape (flurandrenolide) FLUTICASONE PROPIONATE cream, ointment (generic of DESOXIMETASONE cream, gel, ointment (generic of Cutivate®) Topicort®) MOMETASONE FUROATE cream, ointment, solution FLUOCINOLONE ACETONIDE 0.025% cream, ointment (generic of Elocon®) (generic of Synalar®) PREDNICARBATE cream (generic of Dermatop®) FLUTICASONE
    [Show full text]
  • Steroids Topical
    Steroids, Topical Therapeutic Class Review (TCR) September 18, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. September
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • 120.Clobetasol Propionate and [email protected]
    IAJPS 2017, 4 (10), 3779-3786 Harikishor Barange et al ISSN 2349-7750 CODEN (USA): IAJPBB ISSN: 2349-7750 INDO AMERICAN JOURNAL OF PHARMACEUTICALSCIENCES Available online at: http://www.iajps.com Research Article DEVELOPMENT OF ANALYTICAL METHOD AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF CLOBETASOL PROPIONATE AND KETOCONAZOLE IN PHARMACEUTICAL CREAM FORMULATION BY RP-HPLC METHOD Harikishor Barange*, Suhail Asghar and Pooja Gour Unijules Life Sciences Ltd., B - 35, 36 MIDC Area Kalmeshwar Nagpur – 441501, Maharashtra, India. E-mail of Corresponding author: [email protected]. Abstract: A simple, accurate rapid and precise has been developed and validated for simultaneous estimation of Clobetasol Propionate and Ketoconazole in Pharmaceutical Cream Formulation by RP-HPLC Method. The successful estimation was carried out of the drug product is developed on the ODS Qualisil Column C18 (250 mm x 4.6 mm, 5μm or equivalent) at ambient temperature using Methanol: Acetonitrile: Phosphate buffer (50:20:30 v/v/v) as mobile phase composition. The flow rate was adjusted to 1.5mL/minute and the absorption maxima were observed on UV detector at 254 nm. Retention Time for Clobetasole Propionate 11.1±0.1min and Ketoconazole 12.2±0.1min. The linearity was obtained in the concentration range of 6-14µg/mL and 120-280µg/mL for Clobetasole Propionate and Ketoconazole respectively. Mean percentage recoveries were 99.16% for Clobetasole Propionate and 99.17% for Ketoconazole. The LOD of Clobetasole Propionate and Ketoconazole were found to be 0.7μg/mL and 2.0μg/mL whereas the LOQ was 3.0μg/mL and 10.0μg/mL respectively. Percentage relative standard deviation of percent assay values for replicate sample preparation was 0.28% for Clobetasole Propionate and 0.47% for Ketoconazole.
    [Show full text]
  • St John's Institute of Dermatology
    St John’s Institute of Dermatology Topical steroids This leaflet explains more about topical steroids and how they are used to treat a variety of skin conditions. If you have any questions or concerns, please speak to a doctor or nurse caring for you. What are topical corticosteroids and how do they work? Topical corticosteroids are steroids that are applied onto the skin and are used to treat a variety of skin conditions. The type of steroid found in these medicines is similar to those produced naturally in the body and they work by reducing inflammation within the skin, making it less red and itchy. What are the different strengths of topical corticosteroids? Topical steroids come in a number of different strengths. It is therefore very important that you follow the advice of your doctor or specialist nurse and apply the correct strength of steroid to a given area of the body. The strengths of the most commonly prescribed topical steroids in the UK are listed in the table below. Table 1 - strengths of commonly prescribed topical steroids Strength Chemical name Common trade names Mild Hydrocortisone 0.5%, 1.0%, 2.5% Hydrocortisone Dioderm®, Efcortelan®, Mildison® Moderate Betamethasone valerate 0.025% Betnovate-RD® Clobetasone butyrate 0.05% Eumovate®, Clobavate® Fluocinolone acetonide 0.001% Synalar 1 in 4 dilution® Fluocortolone 0.25% Ultralanum Plain® Fludroxycortide 0.0125% Haelan® Tape Strong Betamethasone valerate 0.1% Betnovate® Diflucortolone valerate 0.1% Nerisone® Fluocinolone acetonide 0.025% Synalar® Fluticasone propionate 0.05% Cutivate® Hydrocortisone butyrate 0.1% Locoid® Mometasone furoate 0.1% Elocon® Very strong Clobetasol propionate 0.1% Dermovate®, Clarelux® Diflucortolone valerate 0.3% Nerisone Forte® 1 of 5 In adults, stronger steroids are generally used on the body and mild or moderate steroids are used on the face and skin folds (armpits, breast folds, groin and genitals).
    [Show full text]
  • A List of Medications That May Lower Your Patients' Costs
    A list of medications that may lower your patients’ costs INTRODUCTION Catamaran utilizes a Pharmacy and Therapeutics Committee (P & T Committee), made up of practicing physicians, pharmacists, and nurses to help ensure that our formulary is medically sound and that it supports patient health. This committee reviews and evaluates medications on the formulary based on safety and efficacy to help maintain clinical integrity in all therapeutic categories. FORMULARY DESIGN There are numerous formulary designs that can be used by a pharmacy benefits administrator. Catamaran has chosen a formulary structure which is open and incentive based. Open Formulary: features co‐payments for medications that are preferred and non‐ preferred brands, plus lower co‐payments for generic drugs. Incentive Based: features different co‐payments for medications that are on or off the formulary. In this type of formulary, the patient cost structure may be two‐tier, three‐ tier, or four‐tier design. USING THIS FORMULARY REFERENCE GUIDE TO HELP CONTAIN COSTS Many benefit sponsors use the Catamaran formulary to help manage the overall cost of providing prescription drug benefits. This formulary offers a wide range of medications from which to choose. We realize that this formulary reference guide may not include every drug from every manufacturer. However, choosing a preferred drug when it is appropriate can provide access to the necessary medications to stay healthy, at a cost that is more affordable. KNOWING HOW THE FORMULARY INFORMATION IS ORGANIZED The following formulary reference guide is designed so that generic products are listed first in each drug category. The preferred brand name products are listed next, and non‐preferred brand products are listed last.
    [Show full text]
  • Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services
    Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services Australian Statistics on Medicines 1997 i © Commonwealth of Australia 1998 ISBN 0 642 36772 8 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be repoduced by any process without written permission from AusInfo. Requests and enquiries concerning reproduction and rights should be directed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra, ACT 2601. Publication approval number 2446 ii FOREWORD The Australian Statistics on Medicines (ASM) is an annual publication produced by the Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee. Comprehensive drug utilisation data are required for a number of purposes including pharmacosurveillance and the targeting and evaluation of quality use of medicines initiatives. It is also needed by regulatory and financing authorities and by the Pharmaceutical Industry. A major aim of the ASM has been to put comprehensive and valid statistics on the Australian use of medicines in the public domain to allow access by all interested parties. Publication of the Australian data facilitates international comparisons of drug utilisation profiles, and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes. The data available in the ASM represent estimates of the aggregate community use (non public hospital) of prescription medicines in Australia. In 1997 the estimated number of prescriptions dispensed through community pharmacies was 179 million prescriptions, a level of increase over 1996 of only 0.4% which was less than the increase in population (1.2%).
    [Show full text]
  • LGC Standards Pharmacopoeial Reference Standards 2014
    LL CTS INKSP RODUTO A L P ITH W WEBSHO LGC Standards Pharmacopoeial reference standards 2014 FOR STANDARDS WITH CofA SEE OUR CATALOGUE: PHARMACEUTICAL IMPURITIES AND PRIMARY REFERENCE STANDARDS LGC Quality – ISO Guide 34 • GMP/GLP • ISO 9001 • ISO/IEC 17025 • ISO/IEC 17043 Pharmaceutical impurities Code Product CAS No. CS Price Unit Adiphenine Hydrochloride O LGC Standards N O MM1172.00 Adiphenine Hydrochloride 50-42-0 A 250mg HCl Pharmaceutical impurities and Adrenaline Tartrate OH H OH O OH primary reference standardsMM0614.00 2014 N OH Adrenaline Tartrate 51-42-3 A 500mg OH OH O OH OH H MM0614.02 L-Adrenaline 51-43-4 A 500mg OH N OH Imp. C (EP) as Hydrochloride: 1-(3,4-Di- O H OH MM0614.13 hydroxyphenyl)-2-(methylamino)ethanone 62-13-5 A 100mg N HCl Hydrochloride (Adrenalone Hydrochloride) OH (1R)-1-(3,4-Dihydroxyphenyl)-2- OH O S O MM0614.01 methylaminoethanesulphonic Acid H 78995-75-2 A 100mg OH N (Adrenaline -Sulphonate) OH Alanine NH2 MM0566.00 Alanine 56-41-7 A 500mg OH O Imp. A (Pharmeuropa): (2 S)-2-Aminobutanedioic Acid O NH 2 MM0567.00 OH (Aspartic Acid) 56-84-8 A 500mg OH O Albendazole O H MM0382.00 Albendazole N O 54965-21-8 A 500mg N H S N Imp. A (EP): 5-(Propylsulphanyl)-1H- H MM0382.01 N 80983-36-4 A 100mg NH2 benzimidazol-2-amine S N O H Imp. B (EP): Methyl [5-Propylsulphinyl)- N O MM0382.02 N 54029-12-8 A 100mg H 1H-benzimidazol-2-yl]carbamate S N O O H Imp.
    [Show full text]
  • Mometasone Furoate
    erimenta xp l D E e r & m l a a t c o i l n o i Journal of Clinical & Experimental Molin et al., J Clin Exp Dermatol Res 2013, 4:3 l g y C f R DOI: 10.4172/2155-9554.1000184 o e l ISSN: 2155-9554 s a e n a r r u c o h J Dermatology Research Review Article Open Access Mometasone Furoate: A Well-Established Topical Corticosteroid now with Improved Galenic Formulations Molin S1, Abeck D2, Guilabert A3* and Bellosta M4 1Department of Dermatology and Allergy, Ludwig Maximilian University, München, Bavaria, Germany 2Private Dermatology Munich-Nymphenburg, Germany 3Dermatology Department, Hospital de Granollers, Spain 4Dermatology Practice, Pavia, Italy Abstract Mometasone furoate is an established topical corticosteroid that is frequently used for the treatment of inflammatory skin diseases because it offers a balanced efficacy and safety profile. The type of vehicle of a topical corticosteroid has impact not only on its efficacy but also on the patients’ adherence to treatment. Traditional formulations of mometasone furoate might have not properly fulfilled all the ideal features required for its use in topical treatment. Extensive research has recently been performed and new formulations have been developed that will be available shortly. The aim of this review is to give a thorough overview on the substance mometasone furoate and the available clinical data with a special focus on the newly developed galenic formulations. Keywords: Mometasone furoate; Vehicle; Cream; Emulsion; Scalp Topical Corticosteroids psoriasis; Psoriasis; Atopic eczema Topical corticosteroids are a great family of hydrocortisone- Introduction derivative compounds with variable anti-inflammatory potency and side-effects profile.
    [Show full text]